Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.85 |
| ▸ | TP53 | P04637 | 1/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.85 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.79 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.79 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.79 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91088 | 0.93 | SLC29A1 (0.84) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL17825911 | 0.93 | SLC29A1 (0.84) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL63259 | 0.93 | SLC29A1 (0.84) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL75915 | 0.93 | SLC29A1 (0.84) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL15189026 | 0.93 | SLC29A1 (0.84) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL639447 | 0.93 | SLC29A1 (0.84) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL29697042 | 0.93 | SLC29A1 (0.84) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL17824431 | 0.93 | SLC29A1 (0.84) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL20626300 | 0.93 | SLC29A1 (0.84) | SLC29A1ADORA3TP53TDP1PRKAG1 | |
| SCHEMBL639446 | 0.93 | SLC29A1 (0.84) | SLC29A1ADORA3TP53TDP1PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129357-B2 | N6-(4-hydroxybenzyl)adenosine; Gastrodia extract; neurodegenerative Huntington's disease; trinucleotide repeat disease; hypoglycemic; neurological antiinflammatory; amination of 6-chloropurine ribonucleoside with 4-hydroxybenzylamine; condensation of adenosine with 4-methoxybenzoyl chloride | ACADEMIA SINICA (TW) | 2012-03-06 | — | — | US | disclosed |
| US-20080176816-A1 | Method of making and using an adenosine analogue | ACADEMIA SINICA | 2008-07-24 | — | — | US | disclosed |
| US-7351434-B2 | Therapeutic Gastrodia extracts | ACADEMIA SINICA (TW) | 2008-04-01 | — | — | US | disclosed |
| US-20070237840-A1 | Administering bis(4-hydroxybenzyl)sulfide for therapy of Huntington's disease | ACADEMIA SINICA (TW) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176816-A1 | Method of making and using an adenosine analogue | HTT, ADA, GDA | SLC29A1 38/4885ADORA3 11/4885TP53 3554/4885 |
| US-20070237840-A1 | Administering bis(4-hydroxybenzyl)sulfide for therapy of Huntington's disease | HTT, SNCA, SLC2A4 | SLC29A1 666/4885ADORA3 2549/4885TP53 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.